Predictive role of γ-glutamyltransferase in patients receiving nivolumab therapy for metastatic renal cell carcinoma.
Yudai IshiyamaTsunenori KondoHidekazu TachibanaHiroki IshiharaHironori FukudaKazuhiko YoshidaToshio TakagiJunpei IizukaKazunari TanabePublished in: International journal of clinical oncology (2020)
High baseline γ-glutamyltransferase and its early increase are associated with a poor prognosis in metastatic renal cell carcinoma patients receiving nivolumab. Serum γ-glutamyltransferase levels may help predict treatment outcomes.